Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases

Esther P. Jane(Children's Hospital of Pittsburgh), Ian F. Pollack(Children's Hospital of Pittsburgh)
Molecular Oncology
May 31, 2021
10.1002/1878-0261.13025
Cited by 23

Related Papers

Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|433
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|369
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group
|Neuro-Oncology|2011|342